原著論文1
Ito S, Tsuchida N, Kusunoki S, Kaneko Y, Naito T, Hori S, et al.
afety comparison between Pfizer BNT162b2, Moderna mRNA-1273, and AstraZeneca AZD1222 in a Nationwide prospective cohort survey at the beginning of the severe acute respiratory syndrome coronavirus 2 vaccination in Japan.
Vaccine.
, 49
(126754)
(2025)
doi: 10.1016/j.vaccine.2025.126754.
原著論文2
Shoji N, Ito S, Nojiri S, Urasaki W, Nara T, Okuzawa A, et al.
Adverse reactions to mRNA COVID-19 vaccine in people with allergies in Japan.
Glob Health Med.
, 6
(6)
, 363-374
(2024)
doi: 10.35772/ghm.2024.01053.
原著論文3
Murayama G, Kusaoi M, Horiuchi Y, Tabe Y, Naito T, Ito S, et al.
Effects of the induction of humoral and cellular immunity by third vaccination for SARS-CoV-2.
J Infect Chemother.
, 30
(10)
, 2021-2027
(2024)
doi: 10.1016/j.jiac.2024.03.021.
原著論文4
吉永ゆかり, 伊藤澄信, 大江基貴 他
承認後早期の20歳以上の被接種者(医療従事者)を対象としたファイザー新型コロナウイルスワクチンの一般使用成績調査(初回免疫後12カ月までの追跡調査)
感染症学雑誌
, 98
(5)
, 415-425
(2024)
doi.org/10.11150/kansenshogakuzasshi.e24002
原著論文5
Naito T, Tsuchida N, Kusunoki S, Kaneko Y, Tobita M, Hori S, Ito,S
Reactogenicity and immunogenicity of BNT162b2 or mRNA-1273 COVID-19 booster vaccinations after two doses of BNT162b2 among healthcare workers in Japan: a prospective observational study.
Expert Rev Vaccines.
, 21
(9)
, 1319-1329
(2022)
doi: 10.1080/14760584.2022.2093722.
原著論文6
伊藤澄信
COVID-19ワクチンの安全性モニタリングの実際 大規模コホート調査の実際
薬剤疫学
, 27
(2)
, 71-77
(2022)
https://doi.org/10.3820/jjpe.27.71
原著論文7
Miyamoto S, Numakura K, Kinoshita R, et al.
Serum anti-nucleocapsid antibody correlates of protection from SARS-CoV-2 re-infection regardless of symptoms or immune history.
Commun Med (Lond).
, 5
(1)
, 172-
(2025)
doi: 10.1038/s43856-025-00894-8
原著論文8
Kinoshita R, Miyamoto S, Sakuraba S, et al.
Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence, Japan, 2023.
Emerg Infect Dis.
, 30
(6)
, 1267-1270
(2024)
doi: 10.3201/eid3006.231454